Clinical Trials Open to People Under 18
(123 trials open to new patients)

• Acute Lymphoblastic Leukemia (12 open to new patients)
• Acute Myeloid Leukemia (3 open to new patients)
• Acute Promyelocytic Leukemia (1 open to new patients)
• Adrenal Cortex Carcinoma (1 open to new patients)
• ALK Fusion Protein Expression (1 open to new patients)
• ALK Gene Mutation (1 open to new patients)
• ALK Gene Translocation (1 open to new patients)
• Anal Cancer (1 open to new patients)
• Anemia (1 open to new patients)
• ARAF Gene Mutation (1 open to new patients)
• Astrocytoma (7 open to new patients)
• Atypical Teratoid Rhabdoid Tumor (1 open to new patients)
• Automimmune Diseases (1 open to new patients)
• BCR-ABL1 Fusion Protein Expression (1 open to new patients)
• Benzodiazepine Refractory Status Epilepticus (1 open to new patients)
• Biliary Tract Cancer (1 open to new patients)
• Bone Cancer (1 open to new patients)
• BRAF Gene Mutation (2 open to new patients)
• BRAF NP_004324.2:p.V600X (1 open to new patients)
• Brain Stem Neoplasm (1 open to new patients)
• Brain Tumor (8 open to new patients)
• BRCA 1 Gene Mutation (1 open to new patients)
• BRCA 2 Gene Mutation (1 open to new patients)
• Breast Cancer (3 open to new patients)
• Breast Secretory Carcinoma (1 open to new patients)
• Bronchial Neoplasms (1 open to new patients)
• Cancer, General (10 open to new patients)
• Carcinoma, Bronchogenic (1 open to new patients)
• Cardiovascular Complication (1 open to new patients)
• Cardiovascular Disease (1 open to new patients)
• CD22 Positive (1 open to new patients)
• Central Nervous System Embryonal Neoplasm (1 open to new patients)
• Central Nervous System Embryonal Tumor (2 open to new patients)
• Central Nervous System Ganglioneuroblastoma (1 open to new patients)
• Central Nervous System Neoplasm (15 open to new patients)
• Cholangiocarcinoma (1 open to new patients)
• Chordoma (1 open to new patients)
• Choriocarcinoma (2 open to new patients)
• CNS Malignancies (1 open to new patients)
• CNS Tumor (1 open to new patients)
• Colon Cancer (1 open to new patients)
• Colorectal Cancer (3 open to new patients)
• Congenital Mesoblastic Nephroma (3 open to new patients)
• Cytopenia (1 open to new patients)
• Deleterious ATM Gene Mutation (1 open to new patients)
• Deleterious RAD51C Gene Mutation (1 open to new patients)
• Deleterious RAD51D Gene Mutation (1 open to new patients)
• Desmoid Tumor (1 open to new patients)
• Desmoid-Type Fibromatosis (1 open to new patients)
• Disorders of the Immune System (1 open to new patients)
• Down Syndrome (1 open to new patients)
• Elevated Alpha-Fetoprotein (1 open to new patients)
• Elevated PSA (1 open to new patients)
• Endometrial Cancer (1 open to new patients)
• Ependymal Tumor (1 open to new patients)
• Ependymoma (9 open to new patients)
• Estrogen Receptor Negative (1 open to new patients)
• Ewing Sarcoma (12 open to new patients)
• Extragonadal Embryonal Carcinoma (1 open to new patients)
• FGFR1 Gene Mutation (1 open to new patients)
• FGFR2 Gene Mutation (1 open to new patients)
• FGFR3 Gene Mutation (1 open to new patients)
• FGFR4 Gene Mutation (1 open to new patients)
• Fibrosarcoma (1 open to new patients)
• Ganglioneuroblastoma (3 open to new patients)
• Gastrointestinal Stromal Tumor (1 open to new patients)
• Germ Cell Tumor (10 open to new patients)
• Glioblastoma (6 open to new patients)
• Glioma (22 open to new patients)
• Gliosarcoma (1 open to new patients)
• GNA11 Gene Mutation (2 open to new patients)
• GNAQ Gene Mutation (2 open to new patients)
• Graft Versus Host Disease (1 open to new patients)
• Head and Neck Squamous Cell Carcinoma (1 open to new patients)
• Hematologic Malignancies (1 open to new patients)
• Hematological Malignancy (2 open to new patients)
• Hematopoietic Cell Transplantation Recipient (3 open to new patients)
• Hemispheric (1 open to new patients)
• Hepatoblastoma (10 open to new patients)
• Hepatocellular Carcinoma (2 open to new patients)
• Histiocytic and Dendritic Cell Neoplasm (1 open to new patients)
• Histiocytic Disorders (1 open to new patients)
• Histiocytosis (5 open to new patients)
• HIV/AIDS (1 open to new patients)
• HLA-A*0201 Positive Cells Present (1 open to new patients)
• Hodgkin's Lymphoma (4 open to new patients)
• HRAS Gene Mutation (2 open to new patients)
• IDH1 Gene Mutation (1 open to new patients)
• IDH2 Gene Mutation (1 open to new patients)
• Immunotherapy (1 open to new patients)
• Infantile Fibrosarcoma (1 open to new patients)
• Infection (1 open to new patients)
• Inflammatory Bowel Disease (1 open to new patients)
• Influenza (1 open to new patients)
• Inherited Abnormalities of Platelets (1 open to new patients)
• Inherited Disorders of Metabolism (1 open to new patients)
• Intestinal Neoplasms (1 open to new patients)
• Juvenile Xanthogranuloma (1 open to new patients)
• Kidney Cancer (3 open to new patients)
• KRAS Gene Mutation (2 open to new patients)
• Langerhans Cell Histiocytosis (10 open to new patients)
• Leukemia (16 open to new patients)
• Liposarcoma (1 open to new patients)
• Liver Cancer (2 open to new patients)
• Locally Advanced Chordoma (1 open to new patients)
• Lung Cancer (3 open to new patients)
• Lung Tumor (1 open to new patients)
• Lymphadenopathy (1 open to new patients)
• Lymphoma (21 open to new patients)
• Lymphoproliferative Disorder (1 open to new patients)
• Malignant Central Nervous System Neoplasm (2 open to new patients)
• Malignant Germ Cell Neoplasm (1 open to new patients)
• Malignant Neoplasm (7 open to new patients)
• Malignant Peripheral Nerve Sheath Tumor (1 open to new patients)
• Malignant Solid Neoplasm (18 open to new patients)
• MAP2K1 Gene Mutation (1 open to new patients)
• MAPK1 Gene Mutation (1 open to new patients)
• Matched Targeted Therapy (1 open to new patients)
• Medulloblastoma (11 open to new patients)
• Melanoma (4 open to new patients)
• Metastatic Chordoma (1 open to new patients)
• Metastatic Neoplasm (1 open to new patients)
• Minimal Residual Disease (1 open to new patients)
• MITF Positive (1 open to new patients)
• Multiple Myeloma (2 open to new patients)
• Myelodysplastic Syndrome (2 open to new patients)
• Myeloproliferative Neoplasms (2 open to new patients)
• Neoplasms by Site (1 open to new patients)
• Neoplasms, Nerve Tissue (1 open to new patients)
• Neuroblastoma (24 open to new patients)
• Neurofibromatosis Type 1 (2 open to new patients)
• NF1 Gene Mutation (2 open to new patients)
• NMYC Gene Amplification (1 open to new patients)
• Non Hodgkin Lymphoma (12 open to new patients)
• Non-Small Cell Lung Cancer (1 open to new patients)
• NRAS Gene Mutation (2 open to new patients)
• NTRK1 Fusion Positive (1 open to new patients)
• NTRK2 Fusion Positive (1 open to new patients)
• NTRK3 Fusion Positive (1 open to new patients)
• NY-ESO-1 Positive (1 open to new patients)
• Oligodendroglioma (1 open to new patients)
• Osteosarcoma (12 open to new patients)
• Ovarian Cancer (1 open to new patients)
• Ovarian Embryonal Carcinoma (1 open to new patients)
• Ovarian Tumor (2 open to new patients)
• Pancreatic Cancer (1 open to new patients)
• Pediatric Cancer (1 open to new patients)
• Pediatric Central Nervous System Tumor (1 open to new patients)
• Peripheral Primitive Neuroectodermal Tumor (6 open to new patients)
• Philadelphia Chromosome Positive (1 open to new patients)
• Pineal Region Neoplasm (1 open to new patients)
• Pineoblastoma (1 open to new patients)
• Plexiform Neurofibroma (1 open to new patients)
• Primary Central Nervous System Neoplasm (1 open to new patients)
• Progesterone Receptor Negative (1 open to new patients)
• Prostate Cancer (5 open to new patients)
• PSA Progression (1 open to new patients)
• RB1 Positive (1 open to new patients)
• Recurrent Tumor (1 open to new patients)
• Refractory Central Nervous System Neoplasm (12 open to new patients)
• Refractory Hepatoblastoma (3 open to new patients)
• Refractory Langerhans Cell Histiocytosis (7 open to new patients)
• Refractory Malignant Solid Neoplasm (17 open to new patients)
• Refractory Neurofibromatosis Type 1 (1 open to new patients)
• Refractory Osteosarcoma (6 open to new patients)
• Refractory Tumor (1 open to new patients)
• Renal Cell Carcinoma (3 open to new patients)
• Respiratory Tract Neoplasms (1 open to new patients)
• Rhabdoid Tumor (10 open to new patients)
• Rhabdomyosarcoma (13 open to new patients)
• ROS1 Fusion Positive (1 open to new patients)
• ROS1 Gene Mutation (1 open to new patients)
• ROS1 Gene Translocation (1 open to new patients)
• Salivary Gland Neoplasms (1 open to new patients)
• Sarcoma (18 open to new patients)
• Seminoma (2 open to new patients)
• Skin Cancer/Melanoma (4 open to new patients)
• SMARCB1 Gene Mutation (1 open to new patients)
• Soft Tissue Sarcoma (11 open to new patients)
• Solid Neoplasm (4 open to new patients)
• Solid Tumor (24 open to new patients)
• Spinal Column Tumor (1 open to new patients)
• Squamous Cell Carcinoma (2 open to new patients)
• Stromal Neoplasm (1 open to new patients)
• T Cell Lymphoma (1 open to new patients)
• Teratoma (3 open to new patients)
• Testicular Cancer (1 open to new patients)
• Testicular Tumor (1 open to new patients)
• TFE3 Gene Translocation (1 open to new patients)
• TFEB Gene Translocation (1 open to new patients)
• Thoracic Neoplasms (1 open to new patients)
• Thyroid Cancer (2 open to new patients)
• Thyroid Gland Medullary Carcinoma (1 open to new patients)
• Trisomy 21 (1 open to new patients)
• Trisomy 21 Mosaicism (1 open to new patients)
• TSC1 Gene Mutation (1 open to new patients)
• TSC2 Gene Mutation (1 open to new patients)
• Unresectable Chordoma (1 open to new patients)
• Uterine Cancer (1 open to new patients)
• Uterine Neoplasms (1 open to new patients)
• Wilms Tumor (10 open to new patients)